Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia

ISRCTN ISRCTN21541376
DOI https://doi.org/10.1186/ISRCTN21541376
Secondary identifying numbers 9818P
Submission date
23/11/2005
Registration date
14/03/2006
Last edited
18/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof John Liu Yin
Scientific

Department of Clinical Haematology
Manchester Royal Infirmary
Oxford Road
Manchester
M13 9WL
United Kingdom

Study information

Study designInterventional non-randomised open label trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEvaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
Study objectivesNull hypotheses:
1. The pneumococcal conjugate vaccine (Prevenar) will not provide adequate immunity from pneumococcal disease as measured by antibody levels
2. The pneumococcal conjugate vaccine (Prevenar) does not prime the immune system, resulting in improved responses to subsequent vaccination with the 23-valent polysaccharide vaccine
Ethics approval(s)The proposal was reviewed following submission to Central Office for Research Ethics Committees (COREC) by Salford and Trafford Local Research Ethics Committee on the 8th November 2005. The Research Ethics Committee reference number: 05/Q1404/229. The Committee was content to give a favourable opinion subject to clarification of points raised at the interview. Final approval has now been received dated 28/11/05.
Health condition(s) or problem(s) studiedMultiple myeloma and chronic lymphocytic leukaemia
InterventionAll study participants will be required to undertake three or four scheduled visits. If the patient is being seen regularly for follow up in the clinic, the trial visits will be scheduled to coincide with these to minimise the number of additional attendances.

Visit 1: the potential participants will be informed in detail about the study and given the opportunity to ask any further questions. If they wish to participate they will be formally screened against the exclusion criteria. Provided no contraindications are identified, they will be asked to sign a consent form. Predictable risks and inconveniences will be discussed. A full medical history will be taken, concurrent medication documented and physical examination performed. Details of disease stage will be obtained from the medical records. A case report form has been designed specifically to document all information required and to ensure standardisation. A small blood sample (6 ml) will then be taken for pre-immunisation antibody levels and evaluation of other markers of immune status. Vaccination with the conjugate vaccine will then be administered.

Visit 2: this will take place 8-10 weeks following visit 1. The case report form will be completed in a similar manner. A 2 ml blood sample is required for post-vaccination antibody levels. Following this, the second vaccination with the conjugate vaccine will be administered.

Visit 3: this will take place 8-10 weeks after the second visit. The case report form will be completed. If the patient has received the 23-valent polysaccharide vaccination in the previous five years, the study will terminate at this point and a blood sample will be taken for antibody response and other markers of immune status (6 ml will be required). Subjects who have not received the 23-valent polysaccharide vaccine in the last five years will be vaccinated with this vaccine on this visit. From the group of patients receiving the vaccine only 2 ml of blood is required for post vaccination antibody levels.

Visit 4: only individuals vaccinated at visit 3 will be requested to attend. The visit will take place 6-8 weeks after the third visit. Blood samples will be taken for post immunisation antibody levels and other markers of immune status (6 ml blood).

Participants will also be asked if they would be available to attend for one extra visit for an additional blood test only, one week after the second vaccination. This test is optional and supplementary and aims to evaluate how the vaccine is stimulating another aspect of the immune response (cell mediated immunity), which may also be important in providing protection from disease. 15 ml of blood will be needed for this supplementary test.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Prevenar
Primary outcome measureTo determine whether the pneumococcal conjugate vaccine (Prevenar) can provide immunity from invasive pneumococcal disease in a group of haematology patients at high risk of infective complications
Secondary outcome measures1. To determine whether the immune response to the conjugate vaccine (Prevenar) differs between individuals naive to the 23-valent pneumococcal vaccine and those who have received at least one previous dose
2. To assess whether the response to subsequent vaccination with the 23-valent polysaccharide vaccine is enhanced by prior vaccination with the conjugate vaccine (Prevenar)
3. To determine the optimum dosage and schedule of the conjugate vaccine
4. To evaluate the immune response in relation to disease related variables. These will include disease stage, treatment and laboratory markers of the immune system function as a whole. This will improve our understanding of the mechanisms resulting in vaccine success and failure.
Overall study start date01/12/2005
Completion date30/04/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants97
Key inclusion criteriaPatients with multiple myeloma as defined by the demonstration of:
1. Over 10% plasma cells in the bone marrow and at least one of the following:
a. Lytic lesions on radiographic X-ray imaging
b. A paraprotein in serum or urine
2. Patients with Chronic Lymphocytic Leukemia (CLL) as defined by the demonstration of a clonal population of B-lymphocytes with characteristic immunophenotype (CD5+, CD23+, weak expression of surface Ig (weak SIg), FMC7-negative) in peripheral blood, bone marrow or lymph node biopsy
3. Aged ≥18 years
4. Ability to give written informed consent
Key exclusion criteria1. Immunoglobulin therapy in the previous four months
2. General contraindications to immunisation as defined in the UK handbook - Immunisation against Infectious Disease
3. Currently receiving treatment prior to planned peripheral blood stem cell or bone marrow transplant
4. Less than six months post peripheral blood stem cell or bone marrow transplant
5. Receiving treatment with high dose steroids (monthly pulsed dexamethasone or >1 mg/kg of prednisolone as a continuous dose)
6. Platelets <30 x 10^9 /l
7. Prior vaccination with Prevenar
8. Prior vaccination with 23-valent pneumococcal vaccine in previous six months
9. Pregnancy
10. Previous splenectomy
11. Other secondary immunodeficiency state e.g. Human Immunodeficiency Virus (HIV) infection
Date of first enrolment01/12/2005
Date of final enrolment30/04/2008

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Department of Clinical Haematology
Manchester
M13 9WL
United Kingdom

Sponsor information

Central Manchester and Manchester Children's Hospital (UK)
Hospital/treatment centre

Professor Phillip Sloan
Head of Research and Development
Post Graduate Centre
Manchester Royal Infirmary
Oxford Road
Manchester
M13 9WL
England
United Kingdom

ROR logo "ROR" https://ror.org/00he80998

Funders

Funder type

Charity

Charitable Funds from the Molecular Haematology Fund (9175)

No information available

Contact: Christine Neild

No information available

Charitable Funds Accountant

No information available

Wilmslow Park

No information available

Hathersage Road

No information available

Manchester

No information available

M13 0JR

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

18/10/2017: No publications found, verifying study status with principal investigator.